GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.

The sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estimates of a $3.99 per share loss, GRAIL's revenue fell short of expectations. The company reported revenue of $31.8 million, up from $26.7 million a year earlier, but significantly below the $35.2 million forecast by analysts.

While GRAIL highlighted some positive developments, including encouraging results from its NHS-Galleri trial and a strong cash position of $677.9 million providing runway into 2028, investors seem to remain focused on the revenue miss. As GRAIL continues to develop its multi-cancer early detection tests, the market appears to be reassessing the company's near-term growth prospects, leading to the ongoing pressure on its stock price.